Lowest Price Guaranteed
Pages
252
Last Updated
June 2026
View Count
17204
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Intranasal Therapies
3.3. Mechanism of Intranasal Drug Delivery
3.3.1. Intracellular Pathway
3.3.2. Extracellular Pathway
3.4. Types of Intranasal Drug Formulations
3.5. Types of Intranasal Drug Delivery Systems
3.5.1. Droppers
3.5.2. Unit / Bi-dose Systems
3.5.3. Spray Tips
3.5.4. Dry powder Systems
3.5.5. Multi-dose Systems
3.6. Regulatory Landscape for Intranasal Therapies
3.7. Future Perspectives
4. MARKET LANDSCAPE (DRUG DELIVERY SYSTEMS)
4.1. Chapter Overview
4.2. Intranasal Drug Delivery Systems: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis By Year of Establishment, Company Size and Location of Headquarters
4.2.5. Most Active Players: Analysis by Number of Products
4.3. Intranasal Drug Delivery Systems: Product Landscape
4.3.1. Analysis by Type of Dosage Form
4.3.2. Analysis by Type of System
4.3.3. Analysis by Dosage Volume Range
5. MARKET LANDSCAPE (DRUG PIPELINE)
5.1. Chapter Overview
5.2. Intranasal Therapeutics: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarter
5.2.5. Most Active Players: Analysis by Number of Therapeutics
5.3. Intranasal Therapeutics: Pipeline Review
5.3.1. Analysis by Phase of Development
5.3.2. Analysis by Type of Molecule
5.3.3. Analysis by Target Therapeutic Area
5.3.4. Analysis by Type of Molecule and Phase of Development
5.3.5. Analysis by Type of Molecule and Company Size
5.3.6. Most Active Players: Analysis by Phase of Development
6. COMPANY COMPETITIVENESS ANALYSIS (DRUG DELIVERY SYSTEMS)
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.3.1. Company Competitiveness Analysis: Drug Delivery Systems
6.4. Company Competitiveness: Benchmarking the Capabilities of Leading Players
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Intranasal therapeutics: Clinical Trials Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Status
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Registration Year and Trial Status
7.3.5. Analysis by Enrolled Patient Population and Trial Phase
7.3.6. Analysis by Type of Sponsor / Collaborator
7.3.7. Analysis by Target Patient Group
7.3.8. Analysis by Target Therapeutic Area
7.3.9. Analysis by Study Design
7.3.10. Most Active Players: Analysis by Number of Registered Trials
7.3.11. Analysis by Number of Trials and Geographical Location
7.3.12. Analysis by Number of Trials, Trial Status and Geographical Location
7.3.13. Analysis by Enrolled Patient Population, Trial Status and Geographical Location
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Aptar Pharma
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.4. Recent Developments and Future Outlook
8.3. Nemera
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. Teleflex
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Product Portfolio
8.4.4. Recent Development and Future Outlook
8.5. Mystic Pharmaceuticals
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.3. Recent Development and Future Outlook
8.6. Zeteo Medical
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.3. Recent development and Future Outlook
9. DRUG PROFILES
9.1 Chapter Overview
9.2. TrudhesaTM
9.3. Tyrvaya
9.4. VALTOCO®
9.5. SPRAVATO®
9.6. BAQSIMITM
9.7. NAYZILAM®
9.8. Tosymra®
9.9. XHANCETM
9.10. SINUVA
9.11. NeffyTM
9.12. ZAVEGEPANT (BHV-3500)
9.13. LV-101
9.14. MEDI3250
9.15. DEXANEUROSONE™
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Intranasal Therapeutics and Drug Delivery Systems: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Focus Area
10.3.5. Analysis by Therapeutic Area
10.4. Most Active Players: Analysis by Number of Partnerships
10.5. Analysis by Geography
10.5.1. Country-wise Distribution
10.5.2. Intercontinental and Intracontinental Distribution
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2 Types of Funding
11.3. Intranasal Therapeutics and Drug Delivery Systems: Funding and Investments
11.3.1. Analysis of Number of Funding Instances by Year
11.3.2. Analysis of Amount Invested by Year
11.3.3. Analysis by Number of funding Instances and Type of Funding
11.3.4. Analysis by Amount Invested and Type of Funding
11.3.5. Analysis by Year and Type of Funding
11.3.6. Analysis by Focus Area and Amount Invested
11.3.7. Analysis by Therapeutic Area and Amount Invested
11.3.8. Analysis by Type of Molecule and Amount Invested
11.3.9. Analysis by Geography
11.3.10. Most Active Players: Analysis by Number of Funding Instances
11.3.11. Most Active Investors: Analysis by Amount Invested
11.4. Concluding Remarks
12. START-UP HEALTH INDEXING (DRUG PIPELINE)
12.1. Chapter Overview
12.2. Start-ups in Intranasal Therapeutics
12.2.1. Analysis by Location of Headquarters
12.3. Benchmarking of Start-ups
12.4. Startup-Health Indexing
12.4.1. Analysis by Supplier Strength
12.4.1. Analysis by Pipeline Strength
12.4.2. Analysis by Pipeline Maturity
12.4.4. Analysis by Financial Investments
12.4.5. Analysis by Partnership Activity
12.4.6. Start-ups Health Indexing: Roots Analysis Perspective
13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Intranasal Therapeutics and Drug Delivery Systems: Patent Analysis
13.3.1. Analysis by Publication Year
13.3.2. Analysis by Geography
13.3.3. Analysis by CPC Symbols
13.3.4. Emerging Focus Areas
13.3.5. Analysis by Type of Applicant
13.3.6. Leading Players: Analysis by Number of Patents
13.4. Intranasal Therapeutics and Drug Delivery Systems: Patent Valuation Analysis
13.5. Leading Patents: Analysis by Number of Citations
14. VALUE CHAIN ANALYSIS
14.1. Chapter Overview
14.2. Intranasal Drug Delivery Devices Value Chain
14.3. Cost Distribution Across the Value Chain
14.3.1. Costs Associated with Concept Development and Proof of Concept
14.3.2. Costs Associated with Research and Development
14.3.3. Costs Associated with Regulatory Approvals
14.3.4. Costs Associated Marketing and Sales
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Global Intranasal Therapeutics and Drug Delivery Systems Market, 2022-2035
15.5. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Target Indication, 2022 and 2035
15.6. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Type of Molecule, 2022 and 2035
15.7. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Key Players, 2022 and 2035
15.8. Global Intranasal Therapeutics and Drug Delivery Systems Market: Analysis by Geography, 2022 and 2035
15.9. Intranasal Therapeutics and Drug Delivery Systems: Product-wise Sales Forecast
15.9.1. TRUDHESA (Impel NeuroPharma)
15.9.1.1. Target Patient Population
15.9.1.2. Sales Forecast
15.9.1.3. Net Present Value
15.9.2. VALTOCO (Neurelis)
15.9.2.1. Target Patient Population
15.9.2.2. Sales Forecast
15.9.2.3. Net Present Value
15.9.3. Tyrvaya (Oyster Point Pharma)
15.9.3.1. Target Patient Population
15.9.3.2. Sales Forecast
15.9.3.3. Net Present Value
15.9.4. SPRAVATO (Janssen Pharmaceuticals)
15.9.4.1. Target Patient Population
15.9.4.2. Sales Forecast
15.9.4.3. Net Present Value
15.9.5. BAQSIMI (Eli Lilly)
15.9.5.1. Target Patient Population
15.9.5.2. Sales Forecast
15.9.5.3. Net Present Value
15.9.6. NAYZILAM (UCB)
15.9.6.1. Target Patient Population
15.9.6.2. Sales Forecast
15.9.6.3. Net Present Value
15.9.7. Tosymra (Dr. Reddy’s Laboratories)
15.9.7.1. Target Patient Population
15.9.7.2. Sales Forecast
15.9.7.3. Net Present Value
15.9.8. XHANCE (OptiNose)
15.9.8.1. Target Patient Population
15.9.8.2. Sales Forecast
15.9.8.3. Net Present Value
15.9.9. ONZETRA Xsail (OptiNose)
15.9.9.1. Target Patient Population
15.9.9.2. Sales Forecast
15.9.9.3. Net Present Value
15.9.10. SINUVA (Intersect ENT)
15.9.10.1. Target Patient Population
15.9.10.2. Sales Forecast
15.9.10.3. Net Present Value
15.9.11. Neffy (ARS Pharmaceuticals)
15.9.11.1. Target Patient Population
15.9.11.2. Sales Forecast
15.9.11.3. Net Present Value
15.9.12. MEDI3250 (Daiichi Sankyo)
15.9.12.1. Target Patient Population
15.9.12.2. Sales Forecast
15.9.12.3. Net Present Value
15.9.13. BHV3500 (Biohaven Pharmaceuticals)
15.9.13.1. Target Patient Population
15.9.13.2. Sales Forecast
15.9.13.3. Net Present Value
15.9.14. LV-101 (Levo Therapeutics)
15.9.14.1. Target Patient Population
15.9.14.2. Sales Forecast
15.9.14.3. Net Present Value
15.9.15. BHV-3500 (Biohaven Pharmaceuticals)
15.9.15.1. Target Patient Population
15.9.15.2. Sales Forecast
15.9.15.3. Net Present Value
15.9.16. DEXANEUROSONE (Biomed Industries)
15.9.16.1. Target Patient Population
15.9.16.2. Sales Forecast
15.9.16.3. Net Present Value
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
17. CONCLUDING REMARKS
18. APPENDIX I: TABULATED DATA
19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
Figure 2.1 Executive Summary: Current Market Landscape of Intranasal Drug Delivery Systems
Figure 2.2 Executive Summary: Current Market Landscape of Intranasal Therapeutics
Figure 2.3 Executive Summary: Company Competitiveness Analysis
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Partnerships and Collaborations
Figure 2.6 Executive Summary: Fundings and Investments
Figure 2.7 Executive Summary: Startup-Health Indexing
Figure 2.8 Executive Summary: Patent Analysis
Figure 2.9 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Intracellular Pathway of Intranasal Drug Delivery
Figure 3.2 Extracellular Pathway of Intranasal Drug Delivery
Figure 4.1 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment
Figure 4.2 Intranasal Drug Delivery System Developers: Distribution by Company Size
Figure 4.3 Intranasal Drug Delivery System Developers: Distribution by Location of Headquarters
Figure 4.4 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 4.5 Most Active Players: Distribution by Number of Products
Figure 4.6 Intranasal Drug Delivery Systems: Distribution by Type of Dosage Form
Figure 4.7 Intranasal Drug Delivery Systems: Distribution by Type of System
Figure 4.8 Intranasal Drug Delivery Systems: Distribution by Range of Dosage Volume
Figure 5.1 Intranasal Therapeutic Developers: Distribution by Year of Establishment
Figure 5.2 Intranasal Therapeutic Developers: Distribution by Company Size
Figure 5.3 Intranasal Therapeutic Developers: Distribution by Location of Headquarters
Figure 5.4 Intranasal Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Figure 5.5 Most Active Players: Distribution by Number of Therapeutics
Figure 5.6 Intranasal Therapeutics: Distribution by Phase of Development
Figure 5.7 Intranasal Therapeutics: Distribution by Type of Molecule
Figure 5.8 Intranasal Therapeutics: Distribution by Target Therapeutic Area
Figure 5.9 Intranasal Therapeutics: Distribution by Type of Molecule and Phase of Development
Figure 5.10 Intranasal Therapeutics: Distribution by Type of Molecule and Company Size
Figure 5.11 Most Active Players: Distribution by Phase of Development
Figure 6.1 Company Competitiveness Analysis: Drug Delivery Systems
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.6 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.8 Clinical Trial Analysis: Distribution by Target Patient Group
Figure 7.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 7.10 Clinical Trial Analysis: Distribution by Study Design
Figure 7.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 7.12 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Figure 7.13 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Figure 7.14 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Figure 8.1 Aptar Pharma: Annual Revenues, 2017-9M 2021 (USD Billion)
Figure 8.2 Teleflex: Annual Revenues, 2017-9M 2021 (USD Billion)
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2016- 2021
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Focus Area
Figure 10.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Figure 10.6 Most Active Players: Distribution by Number of Partnerships
Figure 10.7 Partnerships and Collaborations: Distribution by Geography
Figure 10.8 Partnerships and Collaborations: Country-wise Distribution
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Figure 11.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2016-2021
Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2021
Figure 11.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million), 2016-2021
Figure 11.5 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding
Figure 11.6 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 11.7 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Figure 11.8 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Figure 11.9 Funding and Investment Analysis: Distribution of Amount Invested by Type of Molecule (USD Million)
Figure 11.10 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2016-2021
Figure 11.11 Most Active Players: Distribution by Number of Funding Instances
Figure 11.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 11.13 Concluding Remarks
Figure 12.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 12.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 12.3 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 12.4 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 12.5 Startup-Health Indexing: Distribution by Financial Investments
Figure 12.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 12.7 Startup-Health Indexing: Roots Analysis Perspective
Figure 12.8 Spider Web Analysis: Leading Companies
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Publication Year
Figure 13.3 Patent Analysis: Distribution by Type of Patent and Publication Year
Figure 13.4 Patent Analysis: Distribution by Geography
Figure 13.5 Patent Analysis: Distribution by Jurisdiction
Figure 13.6 Patent Analysis: Distribution by CPC Symbols
Figure 13.7 Patent Analysis: Emerging Focus Areas
Figure 13.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 13.9 Leading Industry Players: Distribution by Number of Patents
Figure 13.10 Patent Valuation Analysis: Distribution of Patents by Geography
Figure 13.11 Intranasal Therapeutics and Drug Delivery Systems: Patent Valuation
Figure 14.1 Value Chain Analysis: Intranasal Drug Delivery Devices
Figure 14.2 Cost Distribution Across Value Chain
Figure 14.3 Costs Associated with Concept Development and Proof of Concept
Figure 14.4 Costs Associated with Research and Development
Figure 14.5 Costs Associated with Regulatory Approvals
Figure 14.6 Costs Associated with Marketing and Sales
Figure 15.1 Global Intranasal Therapeutics and Drug Delivery Systems Market, 2022-2035 (USD Million)
Figure 15.2 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Target Indication, 2022 and 2035
Figure 15.3 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Type of Molecule, 2022 and 2035
Figure 15.4 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Key Players, 2022 and 2035
Figure 15.5 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Geography, 2022 and 2035
Figure 15.6 TRUDHESA (Impel NeuroPharma): Estimated Sales, 2022-2035 (USD Million)
Figure 15.7 VALTOCO (Neurelis): Estimated Sales, 2022-2035 (USD Million)
Figure 15.8 Tyrvaya (Oyster Point Pharma): Estimated Sales, 2022-2035 (USD Million)
Figure 15.9 SPRAVATO (Janssen Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.10 BAQSIMI (Eli Lilly): Estimated Sales, 2022-2035 (USD Million)
Figure 15.11 NAYZILAM (UCB): Estimated Sales, 2022-2035 (USD Million)
Figure 15.12 Tosymra (Dr. Reddy’s Laboratories): Estimated Sales, 2022-2035 (USD Million)
Figure 15.13 XHANCE (OptiNose): Estimated Sales, 2022-2035 (USD Million)
Figure 15.14 ONZETRA Xsail (OptiNose): Estimated Sales, 2022-2035 (USD Million)
Figure 15.15 SINUVA (Intersect ENT): Estimated Sales, 2022-2035 (USD Million)
Figure 15.16 Neffy (ARS Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.17 MEDI3250 (Daiichi Sankyo): Estimated Sales, 2022-2035 (USD Million)
Figure 15.18 BHV3500 (Biohaven Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.19 LV-101 (Levo Therapeutics): Estimated Sales, 2022-2035 (USD Million)
Figure 15.20 BHV-3500 (Biohaven Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 15.21 DEXANEUROSONE (Biomed Industries): Estimated Sales, 2022-2035 (USD Million)
Figure 17.1 Concluding Remarks: Current Market Landscape for Intranasal Drug Delivery Systems
Figure 17.2 Concluding Remarks: Current Market Landscape for Intranasal Therapeutics
Figure 17.3 Concluding Remarks: Company Competitiveness Analysis: Intranasal Drug Delivery Systems
Figure 17.4 Concluding Remarks: Clinical Trial Analysis
Figure 17.5 Concluding Remarks: Partnerships and Collaborations
Figure 17.6 Concluding Remarks: Fundings and Investments
Figure 17.7 Concluding Remarks: Startup-Health Indexing
Figure 17.8 Concluding Remarks: Patent Analysis
Figure 17.9 Concluding Remarks: Market Sizing and Opportunity Analysis
Table 3.1 Inhaled and Intranasal Products: Various Guidelines Issued by Regulatory Authorities
Table 4.1 List of Intranasal Drug Delivery System Developers
Table 4.2 List of Intranasal Drug Delivery Systems
Table 5.1 List of Intranasal Therapeutic Developers
Table 5.2 List of Intranasal Therapeutics
Table 6.1 Company Competitiveness: Benchmarking the Capabilities of Leading Players
Table 8.1 Aptar Pharma: Company Overview
Table 8.2 Aptar Pharma: Product Details
Table 8.3 Aptar Pharma: Recent Developments and Future Outlook
Table 8.4 Nemera: Company Overview
Table 8.5 Nemera: Product Details
Table 8.6 Nemera: Future Outlook
Table 8.7 Teleflex: Company Overview
Table 8.8 Teleflex: Product Details
Table 8.9 Teleflex: Future Outlook
Table 8.10 Mystic Pharmaceuticals: Company Overview
Table 8.11 Mystic Pharmaceuticals: Product Details
Table 8.12 Zeteo Biomedical: Company Overview
Table 8.13 Zeteo Biomedical: Product Details
Table 8.14 Zeteo Biomedical: Future Outlook
Table 9.1 Intranasal Therapeutics: List of Drugs
Table 9.2 Drug Profile: Trudhesa (Overview of Drug, Current Development Status and Clinical Results)
Table 9.3 Drug Profile: Tyrvaya (Overview of Drug, Current Development Status and Clinical Results)
Table 9.4 Drug Profile: VALTOCO® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.5 Drug Profile: SPRAVATO® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.6 Drug Profile: BAQSIMITM (Overview of Drug, Current Development Status and Clinical Results)
Table 9.7 Drug Profile: NAYZILAM® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.8 Drug Profile: Tosymra® (Overview of Drug, Current Development Status and Clinical Results)
Table 9.9 Drug Profile: XHANCETM (Overview of Drug, Current Development Status and Clinical Results)
Table 9.10 Drug Profile: SINUVA (Overview of Drug, Current Development Status and Clinical Results)
Table 9.11 Drug Profile: NeffyTM (Overview of Drug, Current Development Status and Clinical Results)
Table 9.12 Drug Profile: Zavegepant (BHV-3500) (Overview of Drug, Current Development Status and Clinical Results)
Table 9.13 Drug Profile: LV-101 (Overview of Drug, Current Development Status and Clinical Results)
Table 10.1 Partnerships and Collaborations: List of Partnerships and Collaborations, 2016-2021
Table 11.1 Intranasal Therapeutics and Drug Delivery Systems: List of Funding and Investment
Table 12.1 Intranasal Therapeutics Start-ups: Distribution by Location of Headquarters
Table 13.1 Patent Analysis: Prominent CPC Symbols
Table 13.2 Patent Analysis: Most Popular CPC Symbols
Table 13.3 Patent Analysis: List of Top CPC Symbols
Table 13.4 Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 13.5 Patent Analysis: List of Relatively High Value Patents
Table 15.1 Intranasal Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
Table 15.2 TRUDHESA: Target Patient Population
Table 15.3 TRUDHESA: Net Present Value (USD Million)
Table 15.4 VALTOCO: Target Patient Population
Table 15.5 VALTOCO: Net Present Value (USD Million)
Table 15.6 Tyrvaya: Target Patient Population
Table 15.7 Tyrvaya: Net Present Value (USD Million)
Table 15.8 SPRAVATO: Target Patient Population
Table 15.9 SPRAVATO: Net Present Value (USD Million)
Table 15.10 BAQSIMI: Target Patient Population
Table 15.11 BAQSIMI: Net Present Value (USD Million)
Table 15.12 NAYZILAM: Target Patient Population
Table 15.13 NAYZILAM: Net Present Value (USD Million)
Table 15.14 Tosymra: Target Patient Population
Table 15.15 Tosymra: Net Present Value (USD Million)
Table 15.16 XHANCE: Target Patient Population
Table 15.17 XHANCE: Net Present Value (USD Million)
Table 15.18 ONZETRA Xsail: Target Patient Population
Table 15.19 ONZETRA Xsail: Net Present Value (USD Million)
Table 15.20 SINUVA: Target Patient Population
Table 15.21 SINUVA: Net Present Value (USD Million)
Table 15.22 Neffy: Target Patient Population
Table 15.23 Neffy: Net Present Value (USD Million)
Table 15.24 MEDI3250: Target Patient Population
Table 15.25 MEDI3250: Net Present Value (USD Million)
Table 15.26 BHV3500: Target Patient Population
Table 15.27 BHV3500: Net Present Value (USD Million)
Table 15.28 LV-101: Target Patient Population
Table 15.29 LV-101: Net Present Value (USD Million)
Table 15.30 BHV-3500: Target Patient Population
Table 15.31 BHV-3500: Net Present Value (USD Million)
Table 15.32 DEXANEUROSONE: Target Patient Population
Table 15.33 DEXANEUROSONE: Net Present Value (USD Million)
Table 18.1 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment
Table 18.2 Intranasal Drug Delivery System Developers: Distribution by Company Size
Table 18.3 Intranasal Drug Delivery System Developers: Distribution by Location of Headquarters
Table 18.4 Intranasal Drug Delivery System Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 18.5 Most Active Players: Distribution by Number of Products
Table 18.6 Intranasal Drug Delivery Systems: Distribution by Type of Dosage Form
Table 18.7 Intranasal Drug Delivery Systems: Distribution by Type of System
Table 18.8 Intranasal Drug Delivery Systems: Distribution by Range of Dosage Volume
Table 18.9 Intranasal Therapeutic Developers: Distribution by Year of Establishment
Table 18.10 Intranasal Therapeutic Developers: Distribution by Company Size
Table 18.11 Intranasal Therapeutic Developers: Distribution by Location of Headquarters
Table 18.12 Intranasal Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Table 18.13 Most Active Players: Distribution by Number of Therapeutics
Table 18.14 Intranasal Therapeutics: Distribution by Phase of Development
Table 18.15 Intranasal Therapeutics: Distribution by Type of Molecule
Table 18.16 Intranasal Therapeutics: Distribution by Target Therapeutic Area
Table 18.17 Intranasal Therapeutics: Distribution by Type of Molecule and Phase of Development
Table 18.18 Intranasal Therapeutics: Distribution by Type of Molecule and Company Size
Table 18.19 Most Active Players: Distribution by Phase of Development
Table 18.20 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 18.21 Clinical Trial Analysis: Distribution by Trial Status
Table 18.22 Clinical Trial Analysis: Distribution by Trial Phase
Table 18.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 18.24 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Trial Phase
Table 18.25 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 18.26 Clinical Trial Analysis: Distribution by Target Patient Group
Table 18.27 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 18.28 Clinical Trial Analysis: Distribution by Study Design
Table 18.29 Most Active Industry Players: Distribution by Number of Registered Trials
Table 18.30 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Table 18.31 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Table 18.32 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Table 18.33 Aptar Pharma: Annual Revenues, 2017-9M 2021 (USD Billion)
Table 18.34 Teleflex: Annual Revenues, 2017-9M 2021 (USD Billion)
Table 18.35 Partnerships and Collaborations: Distribution by Year of Partnership, 2016- 2021
Table 18.36 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.37 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.38 Partnerships and Collaborations: Distribution by Focus Area
Table 18.39 Partnerships and Collaborations: Distribution by Target Therapeutic Area
Table 18.40 Most Active Players: Distribution by Number of Partnerships
Table 18.41 Partnerships and Collaborations: Distribution by Geography
Table 18.42 Partnerships and Collaborations: Country-wise Distribution
Table 18.43 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 18.44 Funding and Investment Analysis: Cumulative Year-wise Distribution of Funding Instances, 2016-2021
Table 18.45 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested (USD Million), 2016-2021
Table 18.46 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2016-2021
Table 18.47 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million), 2016-2021
Table 18.48 Funding and Investment Analysis: Distribution of Instances by Year and Type of Funding
Table 18.49 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 18.50 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area (USD Million)
Table 18.51 Funding and Investment Analysis: Distribution of Amount Invested by Therapeutic Area (USD Million)
Table 18.52 Funding and Investment Analysis: Distribution of Amount Invested by Type of Molecule (USD Million)
Table 18.53 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2016-2021
Table 18.54 Most Active Players: Distribution by Number of Funding Instances
Table 18.55 Most Active Players: Distribution by Amount Invested (USD Million)
Table 18.56 Startup-Health Indexing: Distribution by Location of Headquarters
Table 18.57 Startup-Health Indexing: Distribution by Supplier Strength
Table 18.58 Startup-Health Indexing: Distribution by Pipeline Strength
Table 18.59 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 18.60 Startup-Health Indexing: Distribution by Financial Investments
Table 18.61 Startup-Health Indexing: Distribution by Partnership Activity
Table 18.62 Patent Analysis: Distribution by Type of Patent
Table 18.63 Patent Analysis: Cumulative Distribution by Publication Year
Table 18.64 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 18.65 Patent Analysis: Distribution by Geography
Table 18.66 Patent Analysis: Distribution by Jurisdiction
Table 18.67 Patent Analysis: Distribution by CPC Symbols
Table 18.68 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 18.69 Leading Industry Players: Distribution by Number of Patents
Table 18.70 Patent Valuation Analysis: Distribution of Patents by Geography
Table 18.71 Intranasal Therapeutics and Drug Delivery Systems: Patent Valuation
Table 18.72 Global Intranasal Therapeutics and Drug Delivery Systems Market, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.73 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Target Indication, 2022 and 2035
Table 18.74 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Type of Molecule, 2022 and 2035
Table 18.75 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Key Players, 2022 and 2035
Table 18.76 Global Intranasal Therapeutics and Drug Delivery Systems Market: Distribution by Geography, 2022 and 2035
Table 18.77 TRUDHESA (Impel NeuroPharma): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.78 VALTOCO (Neurelis): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.79 Tyrvaya (Oyster Point Pharma): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.80 SPRAVATO (Janssen Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.81 BAQSIMI (Eli Lilly): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.82 NAYZILAM (UCB): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.83 Tosymra (Dr. Reddy’s Laboratories): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.84 XHANCE (OptiNose): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.85 ONZETRA Xsail (OptiNose): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.86 SINUVA (Intersect ENT): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.87 Neffy (ARS Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.88 MEDI3250 (Daiichi Sankyo): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.89 BHV3500 (Biohaven Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.90 LV-101 (Levo Therapeutics): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.91 BHV-3500 (Biohaven Pharmaceuticals): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 18.92 DEXANEUROSONE (Biomed Industries): Estimated Sales, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Please reach out to our team for the details.
Source: link.springer.com/article/10.1007/s13346-020-00891-5